Form 4: Exelixis CEO Vests Significant Performance-Based Stock

Exelixis, Inc. CEO Michael Morrissey reported the vesting of 548,073 performance-based restricted stock units and a tax-related disposition of 139,524 shares.

Summary

• Michael Morrissey, President and CEO of Exelixis, Inc., reported transactions related to his beneficial ownership of common stock.
• On January 15, 2026, 548,073 shares of common stock were acquired due to the vesting of performance-based restricted stock units (PSUs) at a price of $0.
• These PSUs were part of an award granted on April 3, 2023, covering 313,185 target shares, with eligibility to vest up to 175% of the target shares upon achievement of certain performance criteria.
• The Compensation Committee certified the achievement of performance criteria on January 15, 2026, resulting in the immediate vesting of 50% of the achieved shares.
• The remaining 50% of the achieved shares are scheduled to vest on February 15, 2027, contingent on continuous service.
• Concurrently, 139,524 shares of common stock were disposed of at a price of $45.23 to satisfy tax obligations related to the PSU vesting.
• Following these transactions, Mr. Morrissey directly beneficially owns 1,825,241 shares of common stock.
• His indirect beneficial ownership includes 1,714,404 shares held by the Morrissey Family Living Trust and 17,728 shares in the Exelixis, Inc. 401(k) Plan.
• Direct beneficial ownership also includes 1,690,729 shares to be issued upon vesting of restricted stock units (RSUs) and One-Time Award PSUs granted on March 31, 2025.

Sentiment

Score: 7

Explanation: The filing indicates the achievement of performance criteria for executive compensation, which is generally a positive signal for the company's operational execution. The transactions are routine for executive equity vesting and tax withholding.

Positives

• The Compensation Committee certified the achievement of certain performance criteria, indicating the company met its operational goals tied to executive compensation.
• Michael Morrissey became eligible to vest up to 175% of his target performance-based restricted stock units, reflecting strong performance against set metrics.

Negatives

• A disposition of 139,524 shares occurred to cover tax liabilities associated with the vesting of performance-based restricted stock units, reducing immediate direct holdings.

Future Outlook

The remaining 50% of the performance-based restricted stock units that vested on January 15, 2026, are scheduled to vest on February 15, 2027, subject to Michael Morrissey's continuous service. Additionally, 1,690,729 shares from RSUs and One-Time Award PSUs granted on March 31, 2025, are expected to be issued upon their respective vesting.

Industry Context

This Form 4 filing is a routine disclosure of executive compensation and insider transactions, common in the biotechnology and pharmaceutical industries. It reflects the pre-defined vesting schedule of performance-based equity awards, which are a standard component of executive compensation packages designed to align management incentives with shareholder value creation.

Stakeholder Impact

• Shareholders: The vesting of performance-based awards suggests the company has met certain pre-defined performance metrics, which could be viewed positively as an indicator of operational success.
• Employees: The CEO's compensation structure, including performance-based equity, aligns executive incentives with company performance, potentially motivating broader employee efforts.

Next Steps

• The remaining 50% of the achieved performance-based restricted stock units are scheduled to vest on February 15, 2027, subject to continuous service.
• Issuance of 1,690,729 shares from restricted stock units and One-Time Award PSUs granted on March 31, 2025, will occur upon their respective vesting.

Key Dates

Keywords

Exelixis, EXEL, Michael Morrissey, CEO, Form 4, SEC filing, stock vesting, PSU, RSU, executive compensation, insider transaction, performance-based awards